Probiotic method and composition for maintaining a healthy vaginal microbiome
AssigneeSeed Health, Inc.
InventorsSheri Simmons, Tye Jensen, Joseph E. Kovarik
Life of this patent
Estimating the term…
Abstract
A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual employing a probiotic method and composition for maintaining a healthy vaginal microbiome, with particular embodiments including a bacterial formulation of three distinct species of Lactobacillus crispatus bacteria. In certain embodiments, the bacterial formulation is administered to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists, thereby reducing inflammation in the individual's vagina.
Claims19
A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual, comprising:
- providing a bacterial formulation that includes at least three different, distinct strains of Lactobacillus crispatus, administering the bacterial formulation to an individual's vagina in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists to thereby reduce inflammation in the individual's vagina, wherein the strains of Lactobacillus crispatus are genetically synergistic and inhibit uro-pathogenic E. coli.
A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual, comprising:
- administering to the individual a therapeutically effective amount of a bacterial formulation comprising at least three different strains of Lactobacillus crispatus, wherein the at least three strains of Lactobacillus crispatus are genetically synergistic and inhibit uro-pathogenic E. coli;
- and maintaining the pH of the individual's vagina at below 4.5.
A method to reduce the likelihood of a dysbiosis of the vaginal microbiome in an individual, comprising:
- providing a bacterial formulation that includes at least three different strains of Lactobacillus crispatus;
- administering the bacterial formulation to an individual's vagina in the form of a suppository and in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists to thereby reduce inflammation in the individual's vagina and wherein the bacterial formulation comprises live cells of Lactobacillus crispatus.
Dependencies are inferred from the claim text.